newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • On February 2, 2026, Praxis Precision Medicines' Compensation Committee granted restricted stock unit awards covering 2,964 common shares to eight new non-executive employees.
  • The awards were issued under the 2024 Inducement Plan as material inducements for new hires in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The 2024 Inducement Plan is used exclusively for equity grants to individuals who were not previously employed by the company or returned after a bona fide period of non-employment.
  • The restricted stock units will vest in four equal annual installments, contingent upon continued employment with Praxis on each vesting date.
  • Praxis is a CNS precision neuroscience biopharmaceutical company developing therapies for disorders characterized by neuronal excitation-inhibition imbalance using its Cerebrum™ small molecule platform Solidus™ antisense oligonucleotide platform.